Racura Oncology LtdASX: RAC

EMILI Investor Webinar Nov 2026

· Issued by Racura Oncology Ltd via ASX

Filed with ASX · · 18 pages · English and French

Summary by 6ix AI

Racura Oncology Ltd has announced an investor webinar regarding the EMILI trial, which focuses on a MYC-silencing intervention for acute myeloid leukemia. The trial has received ethics approval from Sheba Medical Center, allowing it to move forward toward patient enrollment expected in the first quarter of the following year. The company plans to expand the trial globally, with additional sites anticipated to open in various regions, contingent on regulatory approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

I N V E S T O R W E B I N A R · 1 9 N O V E M B E R 2 0 2 6 T R I A L S N A P S H O T M I L E S T O N E A C H E I V E D Sheba Medical Center ethics approval EMILI (18 November 2026) P R I N C I P A L I N V E S T I G A T O R Evaluation of a MYC - silencing Intervention in Acute Myeloid LeukemIa...

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

All Racura Oncology news releases